Collaborative centralized reminder/Recall notification to increase immunization rates among young children a comparative effectiveness trial

JAMA Pediatrics

Volumn 169, Issue 4, 2015, Pages 365-373

  Kempe, Allison ^a,b   Saville, Alison W ^a   Dickinson, L Miriam ^a,c,d   Beaty, Brenda ^a,c   Eisert, Sheri ^e,f   Gurfinkel, Dennis ^a   Brewer, Sarah ^a   Shull, Heather ^g   Herrero, Diana ^g   Herlihy, Rachel ^g  

^a CHILDREN S HOSPITAL COLORADO   (United States)

^b University of Colorado Denver and Children s Hospital Colorado   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

^g Air Pollution Control Division   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHILD; CHILDHOOD DISEASE; COLLABORATIVE CENTRALIZED APPROACH; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FINANCIAL MANAGEMENT; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MEDICAL INFORMATION SYSTEM; PATIENT CARE; PRACTICE BASED REMINDER RECALL APPROACH; PRESCHOOL CHILD; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; INFANT; PRIMARY HEALTH CARE; REMINDER SYSTEM; UTILIZATION;

CHILD, PRESCHOOL; COLORADO; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION; INFANT; PRIMARY HEALTH CARE; REMINDER SYSTEMS;

EID: 84928242074     PISSN: 21686203     EISSN: 21686211     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2014.3670     Document Type: Article

References (47)

1. Zhou F, Shefer A,Wenger J, et al. Economic evaluation of the routine childhood immunization program in the United States, 2009. Pediatrics. 2014;133(4):577-585
2. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among children aged 19-35 months: United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:689-696
3. US Department of Health and Human Services Office of Disease Prevention and Health Promotion. Healthy People 2020. October 30, 2012. http://www.healthypeople.gov/2020/topicsobjectives2020/default. Accessed February 7, 2013
4. Szilagyi PG, Bordley C, Vann JC, et al. Effect of patient reminder/recall interventions on immunization rates: a review. JAMA. 2000;284 (14):1820-1827
5. Szilagyi P, Vann J, Bordley C, et al. Interventions aimed at improving immunization rates. Cochrane Database Syst Rev. 2002;(4):CD003941
6. Briss PA, Rodewald LE, Hinman AR, et al; Task Force on Community Preventive Services. Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults. Am J Prev Med. 2000;18(1)(suppl):97-140
7. Task Force on Community Preventive Services. Recommendations regarding interventions to improve vaccination coverage in children, adolescents, and adults. Am J Prev Med. 2000;18(1) (suppl):92-96
8. Tierney CD, Yusuf H, McMahon SR, et al. Adoption of reminder and recallmessages for immunizations by pediatricians and public health clinics. Pediatrics. 2003;112(5):1076-1082
9. Clark SJ, Cowan AE, Bartlett DL. Private provider participation in statewide immunization registries. BMC Public Health. 2006;6:33. doi:10.1186/1471-2458-6-33
10. Dombkowski KJ, Cowan AE, Harrington LB, Allred NJ, Hudson E, Clark SJ. Feasibility of initiating and sustaining registry-based immunization recall in private practices. Acad Pediatr. 2012;12(2):104-109
11. Kempe A, Saville A, Dickinson LM, et al. Population-based vs practice-based recall for childhood immunizations: a randomized controlled comparative effectiveness trial. Am J Public Health. 2013;103(6):1116-1123
12. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ. 2009;180(10):47-57
13. Department of Health and Human Services. NIH Health Care Systems Research Collaboratory-Pragmatic Clinical Trials Demonstration Projects (UH2/UH3). January 24, 2012. http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-12-002.html. Accessed July 31, 2012
14. Colorado Department of Public Health and Environment CIIS. Colorado Annual Immunization Progress Report for CY2011. Denver, CO: Immunization Information Systems; 2011
15. Colorado Rural Health Center. Colorado: county designations, 2014. https://coruralhealth.org/wp-content/uploads/2013/10/2014.Colorado-County-Designations.pdf. Accessed January 23, 2015
16. Centers for Disease Control and Prevention. Recommended immunization schedule for persons age 0 through 18 years: United States, 2014. http://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html. Accessed December 11, 2014
17. Raab GM, Butcher I. Balance in cluster randomized trials. Stat Med. 2001;20(3):351-365
18. Glynn RJ, BrookhartMA, Stedman M, Avorn J, Solomon DH. Design of cluster-randomized trials of quality improvement interventions aimed at medical care providers. Med Care. 2007;45(10) (suppl 2):S38-S43
19. Ivers NM, Halperin IJ, Barnsley J, et al. Allocation techniques for balance at baseline in cluster randomized trials: amethodological review. Trials. 2012;13:120. doi:10.1186/1745-6215-13-120
20. Moulton LH. Covariate-based constrained randomization of group-randomized trials. Clin Trials. 2004;1(3):297-305
21. US Department of Justice. The Freedom of Information Act (FOIA). September 1, 2014
22. Littel RC, Milliken GA, StroupWW,Wolfinger RD. SAS Systemfor Mixed Models. Cary, NC: SAS Institute Inc; 1999
23. Raudenbush SW, Bryk AS. Hierarchical Linear Models: Applications and Data AnalysisMethods (Advanced Quantitative Techniques in the Social Sciences). 2nd ed. Newbury Park, CA: Sage Publications Inc; 2001
24. Bureau of Labor Statistics. Occupational employment statistics. http://www.bls.gov/oes/2011/may/oes-co.htm. Accessed January 12, 2015
25. Jacobson Vann JC, Szilagyi P. Patient reminder and patient recall systems to improve immunization rates [update of Cochrane Database Syst Rev. 2002;(4):CD003941]. Cochrane Database Syst Rev. 2005;(3):CD003941
26. Saville AW, Albright K, Nowels C, et al. Getting under the hood: exploring issues that affect provider-based recall using an immunization information system. Acad Pediatr. 2011;11(1):44-49
27. Albright K, Saville A, Lockhart S,Widmer Racich K, Beaty B, Kempe A. Provider attitudes toward public-private collaboration to improve immunization reminder/recall: amixed-methods study. Acad Pediatr. 2014;14(1):62-70
28. Kempe A, DaleyMF, Pyrzanowski J, et al. School-located influenza vaccination with third-party billing: what do parents think? Acad Pediatr. 2014;14(3):241-248
29. Saville AW, Beaty B, Dickinson LM, Lockhart S, Kempe A. Novel immunization reminder/recall approaches: rural and urban differences in parent perceptions. Acad Pediatr. 2014;14(3):249-255
30. Zhou F, Santoli J,Messonnier ML, et al. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch Pediatr Adolesc Med. 2005;159 (12):1136-1144
31. Zhou F, Bisgard KM, Yusuf HR, Deuson RR, Bath SK, Murphy TV. Impact of universal Haemophilus influenzae type B vaccination starting at 2 months of age in the United States: an economic analysis. Pediatrics. 2002;110(4):653-661
32. Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000;283(11):1460-1468
33. Ekwueme DU, Strebel PM, Hadler SC, Meltzer MI, Allen JW, Livengood JR. Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. Arch Pediatr Adolesc Med. 2000;154(8):797-803
34. Fendrick AM, Lee JH, LaBarge C, Glick HA. Clinical and economic impact of a combination Haemophilus influenzae and hepatitis B vaccine: estimating cost-effectiveness using decision analysis. Arch Pediatr Adolesc Med. 1999;153(2): 126-136
35. MillerMA, Sutter RW, Strebel PM, Hadler SC. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA. 1996;276(12): 967-971
36. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA. 1995; 274(15):1201-1208
37. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA. 1994;271(5):375-381
38. Huse DM, Meissner HC, LaceyMJ, Oster G. Childhood vaccination against chickenpox: an analysis of benefits and costs. J Pediatr. 1994;124 (6):869-874
39. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med. 1993;118(4):298-306
40. Hay JW, Daum RS. Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type B infection. Pediatrics. 1987;80(3):319-329
41. Cochi SL, Broome CV, Hightower AW. Immunization of US children with Hemophilus influenzae type B polysaccharide vaccine: a cost-effectiveness model of strategy assessment. JAMA. 1985;253(4):521-529
42. White CC, Koplan JP, OrensteinWA. Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health. 1985;75(7): 739-744
43. Hinman AR, Koplan JP. Pertussis and pertussis vaccine: reanalysis of benefits, risks, and costs. JAMA. 1984;251(23):3109-3113
44. Mulley AG, SilversteinMD, Dienstag JL. Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. N Engl J Med. 1982;307 (11):644-652
45. Koplan JP, Preblud SR. A benefit-cost analysis of mumps vaccine. Am J Dis Child. 1982;136(4): 362-364
46. Albritton RB. Cost-benefits of measles eradication: effects of a federal intervention. Policy Anal. 1978;4(1):1-21
47. Schoenbaum SC, Hyde JN Jr Bartoshesky L, Crampton K. Benefit-cost analysis of rubella vaccination policy. N Engl J Med. 1976;294(6): 306-310.